The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer

Title:The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer

Volume: 21 Issue: 12

Author(s): Monireh Mohsenzadegan, Parizad Bavandpour, Mohammad Reza Nowroozi, Erfan Amini, Masoumeh Kourosh-Arami, Seyed Ali Momeni, Saied Bokaie and Laleh Sharifi*

Affiliation:

• Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran,Iran

Keywords: Bladder cancer, T-cell immunoglobulin and mucin domain 3 (TIM-3), checkpoint inhibitor, inhibitory receptor, immunotherapy, monoclonal antibodies, anti-cancer treatment.

Abstract: Targeting inhibitory receptors on T cells in the tumor sites can promote effective anti-tumor immunity in bladder cancer. Unfortunately, the main dilemma is that a large number of patients remain refractory to CTLA-4, PD-1, and PD-L1 blockade therapies. T-cell immunoglobulin and mucin domain 3 (Tim-3) is an inhibitory receptor expressed on T cells and innate immune cells. Both in vivo and in vitro data from patients with advanced cancers support the role of Tim-3 inhibition in satisfactory anti-tumor immunity. In bladder cancer, the expression level of Tim-3 significantly increases with advanced pathological grade and T stage. Therefore, rationality implies that designing novel monoclonal antibodies reactive with Tim-3 alone or in combination with other checkpoint inhibitors may indicate a favorable response in bladder cancer. Here, we aimed to investigate the possibility of targeting Tim-3 as a novel anti-cancer treatment for bladder cancer.

Cite this article as:

Mohsenzadegan Monireh, Bavandpour Parizad , Nowroozi Reza Mohammad, Amini Erfan , Kourosh-Arami Masoumeh, Momeni Ali Seyed , Bokaie Saied and Sharifi Laleh *, The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (12) . https://dx.doi.org/10.2174/1871530321666210310142141